Cyclacel Pharmaceuticals Amends Its Sapacitabine License Agreement With Daiichi-Sankyo

Cyclacel Pharmaceuticals, Inc. CYCC, today announced that effective July 11, 2011, Cyclacel Limited, a wholly-owned subsidiary of the Company, entered into an amendment of its license agreement, dated September 10, 2003 between Cyclacel Limited and Daiichi Sankyo Company, Limited relating to certain rights which Cyclacel Limited has licensed from Daiichi Sankyo with regard to the Company's sapacitabine drug.